Microbot Medical announced today that it began the U.S. commercial launch of its Liberty endovascular surgical robot.

HINGHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributer of the innovative LIBERTY ® Endovascular Robotic System, today announced that it will ...

Company Completes the Required Infrastructure to Support the Introduction of LIBERTY® to the U.S. Market with the Hiring of the Core Commercial ...

Microbot Medical (MBOT) concludes 2024 with the achievement of several key milestones, including the recent FDA 510(k) submission for FDA commercial approval of LIBERTY, which the company believes ...

HINGHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY ® Endovascular Robotic System, today announced that the ...

Microbot Medical Inc. has announced the addition of two senior executives to enhance its U.S. commercial leadership team in preparation for the upcoming launch of its LIBERTY® Endovascular Robotic ...

HINGHAM, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its ...

Microbot Medical ( ($MBOT) ) has issued an announcement. On November 5, 2025, Microbot Medical announced the limited commercial availability of ...

Microbot Medical Inc. (NASDAQ:MBOT) is one of the best-performing NASDAQ stocks according to analysts. On June 17, Microbot Medical announced that it had been granted a patent in China by the China ...

Microbot Medical Inc., developer and manufacturer of the innovative Liberty Endovascular Robotic System, announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the ...